Taiwan’s Pharmaceutical Affairs Act grants data exclusivity to encourage innovation. New drugs with novel ingredients receive three years of exclusivity, preventing others from using their data for generic registration. Modified or new indications can receive two years if submitted within two years of foreign approval. This protects research investments while promoting competition.